Rep. Tim Moore Buys Genprex (NASDAQ:GNPX) Shares

Representative Tim Moore (R-North Carolina) recently bought shares of Genprex (NASDAQ:GNPX). In a filing disclosed on November 12th, the Representative disclosed that they had bought between $15,001 and $50,000 in Genprex stock on October 29th. The trade occurred in the Representative’s “SCHWAB ONE” account.

Representative Tim Moore also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 10/31/2025.
• Purchased $15,001 – $50,000 in shares of LGI Homes (NASDAQ:LGIH) on 10/30/2025.
• Sold $100,001 – $250,000 in shares of Hyster-Yale (NYSE:HY) on 10/24/2025.
• Sold $50,001 – $100,000 in shares of Krispy Kreme (NASDAQ:DNUT) on 10/22/2025.
• Purchased $15,001 – $50,000 in shares of Hyster-Yale (NYSE:HY) on 10/14/2025.
• Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 10/10/2025.
• Purchased $15,001 – $50,000 in shares of Hyster-Yale (NYSE:HY) on 10/10/2025.
• Purchased $50,001 – $100,000 in shares of Hyster-Yale (NYSE:HY) on 10/8/2025.
• Purchased $50,001 – $100,000 in shares of Verizon Communications (NYSE:VZ) on 10/7/2025.
• Sold $50,001 – $100,000 in shares of Hyster-Yale (NYSE:HY) on 9/19/2025.

Genprex Trading Down 9.5%

Shares of NASDAQ:GNPX traded down $0.35 during trading on Wednesday, hitting $3.34. 288,284 shares of the stock were exchanged, compared to its average volume of 265,381. The company has a market cap of $4.18 million, a PE ratio of -0.13 and a beta of -0.74. The company has a fifty day moving average price of $10.06 and a two-hundred day moving average price of $11.68. Genprex has a 12-month low of $3.23 and a 12-month high of $68.50.

Genprex (NASDAQ:GNPX) last posted its earnings results on Friday, November 14th. The company reported ($5.00) earnings per share for the quarter, beating the consensus estimate of ($12.50) by $7.50. Equities research analysts anticipate that Genprex will post -5.7 earnings per share for the current fiscal year.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP raised its holdings in Genprex (NASDAQ:GNPX) by 11.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the period. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 at the end of the most recent reporting period. 14.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on GNPX. Wall Street Zen upgraded shares of Genprex to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Representative Moore

Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina’s 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Moore (Republican Party) ran for election to the U.S. House to represent North Carolina’s 14th Congressional District. He won in the general election on November 5, 2024.

Moore served as speaker of the House from 2015 to 2025.

Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.